Last reviewed · How we verify
Allergovac Poliplus
Allergovac Poliplus is an allergen immunotherapy vaccine designed to desensitize the immune system to multiple allergens through controlled exposure.
Allergovac Poliplus is an allergen immunotherapy vaccine designed to desensitize the immune system to multiple allergens through controlled exposure. Used for Allergic rhinitis and/or allergic asthma caused by multiple allergens.
At a glance
| Generic name | Allergovac Poliplus |
|---|---|
| Sponsor | Roxall Medicina España S.A |
| Drug class | Allergen immunotherapy vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology / Allergy |
| Phase | Phase 2 |
Mechanism of action
This polyvalent allergen extract vaccine works by inducing immune tolerance to common allergens, likely through mechanisms of T-regulatory cell expansion and shift from Th2 to Th1/Treg responses. By gradually exposing patients to increasing doses of multiple allergen extracts, the vaccine aims to reduce allergic symptoms and the need for symptomatic medications.
Approved indications
- Allergic rhinitis and/or allergic asthma caused by multiple allergens
Common side effects
- Local injection site reactions (erythema, swelling, pruritus)
- Systemic allergic reactions
- Anaphylaxis
Key clinical trials
- Study to Evaluate the Efficacy and Safety of "Allergovac Poliplus" in Polysensitized Patients With Allergic Rhinitis/Rhinoconjunctivitis, With or Without Asthma
- Evaluation of Tolerability and Safety of "Allergovac Poliplus" in Polysensitized Patients With Rhinitis or Allergic Rhinoconjunctivitis With or Without Asthma: A Study in Daily Clinical Practice
- A Trial With Subcutaneous Immunotherapy (SCIT) in Patients With Rhinoconjunctivitis Sensitized to Olea Europaea and Phleum Pratense (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Allergovac Poliplus CI brief — competitive landscape report
- Allergovac Poliplus updates RSS · CI watch RSS
- Roxall Medicina España S.A portfolio CI